Melanotan II (10MG)

Melanotan II — a 7-residue cyclic melanocortin-receptor-agonist research peptide — supplied by BioFusion as a vacuum-sealed lyophilized 10mg vial for MC1R/MC4R receptor-binding research chemistry.

Research context

Melanotan II is the canonical reference compound for melanocortin-receptor research panels. The 7-residue cyclic structure (Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂, with a lactam bridge between Asp² and Lys⁷) provides high binding affinity at MC1R, MC3R, MC4R, and MC5R subtypes. Frequently studied alongside the related PT-141 (bremelanotide) in receptor-subtype-selectivity research.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility, with the on-resin lactam-bridge cyclization step performed pre-cleavage. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). The Fmoc primer covers the on-resin cyclization decision.

Storage & handling

Lyophilized Melanotan II is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling. The cyclic structure is robust under typical research-handling conditions. The reconstitution calculator handles working-concentration math for 10mg-vial protocols.

Why BioFusion

On-resin lactam-bridge cyclization is technically demanding — incomplete cyclization produces linear by-products with very different receptor-binding profiles. BioFusion’s Melanotan II is verified by LC-MS for the cyclized form (mass loss = 18 Da relative to linear precursor) and by analytical HPLC for purity ≥99.0%. Batch transparency ledger publishes per-lot data. Bulk discounts at three+; members save 25%.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.